These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

441 related items for PubMed ID: 22404694

  • 1. Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis.
    Costa LJ, Kramer C, Hogan KR, Butcher CD, Littleton AL, Shoptaw KB, Kang Y, Stuart RK.
    Transfusion; 2012 Nov; 52(11):2375-81. PubMed ID: 22404694
    [Abstract] [Full Text] [Related]

  • 2. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
    Lor KW, Helmons PJ, Belew H, Lane JR, Ball ED.
    Pharmacotherapy; 2012 Jul; 32(7):596-603. PubMed ID: 22760691
    [Abstract] [Full Text] [Related]

  • 3. Mobilization of Hematopoietic Progenitor Cells for Autologous Transplantation Using Pegfilgrastim and Plerixafor: Efficacy and Cost Implications.
    Watts NL, Marques MB, Peavey DB, Innis-Shelton R, Saad A, Ad S, Salzman D, Lamb LS, Costa LJ.
    Biol Blood Marrow Transplant; 2019 Feb; 25(2):233-238. PubMed ID: 30219699
    [Abstract] [Full Text] [Related]

  • 4. Retrospective comparison of filgrastim plus plerixafor to other regimens for remobilization after primary mobilization failure: clinical and economic outcomes.
    Perkins JB, Shapiro JF, Bookout RN, Yee GC, Anasetti C, Janssen WE, Fernandez HF.
    Am J Hematol; 2012 Jul; 87(7):673-7. PubMed ID: 22674468
    [Abstract] [Full Text] [Related]

  • 5. Pegfilgrastim improves the outcomes of mobilization and engraftment in autologous hematopoietic stem cell transplantation for the treatment of multiple myeloma.
    Ding X, Huang W, Peng Y, Fan H, Zhu Y, Liu X, Yang Y, Guo Q, Qiu L, Dai Y, Zou D, Jin F.
    Ann Hematol; 2020 Jun; 99(6):1331-1339. PubMed ID: 32382775
    [Abstract] [Full Text] [Related]

  • 6. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization.
    Costa LJ, Alexander ET, Hogan KR, Schaub C, Fouts TV, Stuart RK.
    Bone Marrow Transplant; 2011 Jan; 46(1):64-9. PubMed ID: 20383210
    [Abstract] [Full Text] [Related]

  • 7. Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use.
    Veltri L, Cumpston A, Shillingburg A, Wen S, Luo J, Leadmon S, Watkins K, Craig M, Hamadani M, Kanate AS.
    Cytotherapy; 2015 Dec; 17(12):1785-92. PubMed ID: 26475754
    [Abstract] [Full Text] [Related]

  • 8. Plerixafor plus pegfilgrastim is a safe, effective mobilization regimen for poor or adequate mobilizers of hematopoietic stem and progenitor cells: a phase I clinical trial.
    Herbert KE, Demosthenous L, Wiesner G, Link E, Westerman DA, Came N, Ritchie DS, Harrison S, Seymour JF, Prince HM.
    Bone Marrow Transplant; 2014 Aug; 49(8):1056-62. PubMed ID: 24887382
    [Abstract] [Full Text] [Related]

  • 9. Tbo-Filgrastim versus Filgrastim during Mobilization and Neutrophil Engraftment for Autologous Stem Cell Transplantation.
    Elayan MM, Horowitz JG, Magraner JM, Shaughnessy PJ, Bachier C.
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1921-5. PubMed ID: 26033279
    [Abstract] [Full Text] [Related]

  • 10. Growth factor plus preemptive ('just-in-time') plerixafor successfully mobilizes hematopoietic stem cells in multiple myeloma patients despite prior lenalidomide exposure.
    Costa LJ, Abbas J, Hogan KR, Kramer C, McDonald K, Butcher CD, Littleton A, Shoptaw K, Kang Y, Stuart RK.
    Bone Marrow Transplant; 2012 Nov; 47(11):1403-8. PubMed ID: 22484324
    [Abstract] [Full Text] [Related]

  • 11. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
    Nademanee AP, DiPersio JF, Maziarz RT, Stadtmauer EA, Micallef IN, Stiff PJ, Hsu FJ, Bridger G, Bolwell BJ.
    Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of hematopoietic stem cell mobilization strategies including plerixafor in multiple myeloma and lymphoma patients.
    Tichopád A, Vítová V, Kořístek Z, Lysák D.
    J Clin Apher; 2013 Dec; 28(6):395-403. PubMed ID: 23922227
    [Abstract] [Full Text] [Related]

  • 13. Preemptive Approach to Plerixafor Use Is Optimal in Patients With Relapsed/Refractory Germ Cell Tumors Undergoing Peripheral Blood Hematopoietic Stem Cell Collection: Effect on Collection Days, Yields, and Cost.
    Sohutskay DO, Tetrick AM, Goebel WS, Schwering D, Reddy MS.
    J Clin Apher; 2024 Oct; 39(5):e22145. PubMed ID: 39291715
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of pre-emptively used plerixafor in patients mobilizing poorly after chemomobilization: a single centre experience.
    Jantunen E, Kuittinen T, Mahlamäki E, Pyörälä M, Mäntymaa P, Nousiainen T.
    Eur J Haematol; 2011 Apr; 86(4):299-304. PubMed ID: 21198864
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. GCSF with or without chemotherapy compared to Plerixafor with GCSF as salvage mobilization regimen in patients with multiple myeloma and lymphoma: collection effectiveness and cost effectiveness analysis.
    Abdel-Rahman F, Tuffaha HW, Sharma S, Jazar HA, Hussein N, Saad A, Al Rawi O, Hussein A.
    J Oncol Pharm Pract; 2014 Apr; 20(2):130-6. PubMed ID: 23676506
    [Abstract] [Full Text] [Related]

  • 18. Long-active granulocyte colony-stimulating factor for peripheral blood hematopoietic progenitor cell mobilization.
    Martino M, Laszlo D, Lanza F.
    Expert Opin Biol Ther; 2014 Jun; 14(6):757-72. PubMed ID: 24597960
    [Abstract] [Full Text] [Related]

  • 19. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide.
    Shaughnessy P, Islas-Ohlmayer M, Murphy J, Hougham M, MacPherson J, Winkler K, Silva M, Steinberg M, Matous J, Selvey S, Maris M, McSweeney PA.
    Biol Blood Marrow Transplant; 2011 May; 17(5):729-36. PubMed ID: 20813198
    [Abstract] [Full Text] [Related]

  • 20. A retrospective study of autologous stem cell mobilization to guide an immediate salvage protocol using plerixafor for patients who mobilize stem cells poorly.
    Hay AE, Lawrie A, Robinson N, Dong B, Culligan DJ.
    J Clin Apher; 2013 Oct; 28(5):378-80. PubMed ID: 23483573
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.